# RETEVMO

NDC: 0002-2980
Generic name: selpercatinib
Labeler / Manufacturer: Eli Lilly and Company
Product type: HUMAN PRESCRIPTION DRUG
Marketing category: New Drug Application (innovator)
Dosage form: CAPSULE
Routes: ORAL
Marketing started: 20200508

FDA application: NDA213246

## Active ingredients

- SELPERCATINIB: 80 mg/1

## Pharmacological class

—

## External sources

- openFDA: https://api.fda.gov/drug/ndc.json?search=product_ndc:"0002-2980"
- FDA NDC Directory: https://www.accessdata.fda.gov/scripts/cder/ndc/dsp_searchresult.cfm?p_ndc=0002-2980
- DailyMed: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7fa848ba-a59c-4144-9f52-64d090f4d828